Drugs / Ongericimab
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05859529 | May → Jun 2023 | — | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05128539 | Feb 2022 → Nov 2023 | — | Shanghai Junshi Bioscience Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04469673 | May 2019 → May 2020 | hyperlipidemia | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07106034 | Aug 2025 → Jul 2027 expected | colorectal cancer | Shanghai Pudong Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04515927 | Aug 2020 → May 2022 | hyperlipidemia | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07242599 | Apr 2026 → Apr 2029 expected | cerebral infarction | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05532800 | Feb 2022 → Feb 2023 | hyperlipidemia | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05325203 | Dec 2021 → May 2023 | familial hypercholesterolemia | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04781114 | Dec 2020 → May 2022 | hyperlipidemia | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04197817 Comparator | Dec 2017 → Aug 2018 | hyperlipidemia | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05621070 Comparator | Feb 2023 → Sep 2024 overdue | hyperlipoproteinemia | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ongericimab | “This phase 3 trial aims to evaluate the efficacy and safety of ongericimab, a novel monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), in...” PMID 39999660 ↗ Jan 2025 |
| Known as | JS002 | “JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody.” NCT04781114 ↗7“JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody.” NCT05532800 ↗ |
| Action | Inhibit | “PCSK9 Inhibitor (JS002)” NCT04197817 ↗ |
| Modality | Monoclonal antibody | “JS002 is a recombinant humanized Anti- PCSK9 monoclonal antibody” NCT04197817 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of JS002” NCT04197817 ↗ |
| Target | PCSK9 | “anti-PCSK9” NCT04469673 ↗ |